BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28785832)

  • 1. A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay.
    Bianchi F; Maccaroni E; Belvederesi L; Brugiati C; Giampieri R; Bini F; Bracci R; Pagliaretta S; Del Prete M; Piva F; Mandolesi A; Scarpelli M; Berardi R
    Fam Cancer; 2018 Apr; 17(2):215-224. PubMed ID: 28785832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A missense germline mutation in exon 7 of the MSH2 gene in a HNPCC family from center-Italy.
    Bianchi F; Galizia E; Porfiri E; Belvederesi L; Catalani R; Loretelli C; Bracci R; Bearzi I; Turchi C; Viel A; Cellerino R
    Fam Cancer; 2007; 6(1):97-102. PubMed ID: 17165155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins.
    Jaballah-Gabteni A; Tounsi H; Kabbage M; Hamdi Y; Elouej S; Ben Ayed I; Medhioub M; Mahmoudi M; Dallali H; Yaiche H; Ben Jemii N; Maaloul A; Mezghani N; Abdelhak S; Hamzaoui L; Azzouz M; Boubaker S
    J Transl Med; 2019 Jun; 17(1):212. PubMed ID: 31248416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
    Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
    Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
    Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour characteristics provide evidence for germline mismatch repair missense variant pathogenicity.
    Li S; Qian D; Thompson BA; Gutierrez S; Wu S; Pesaran T; LaDuca H; Lu HM; Chao EC; Black MH
    J Med Genet; 2020 Jan; 57(1):62-69. PubMed ID: 31391288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families.
    Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C;
    Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel missense MSH2 gene mutation in a patient of a Korean family with hereditary nonpolyposis colorectal cancer.
    Park SJ; Lee KA; Park TS; Kim NK; Song J; Kim BY; Choi JR
    Cancer Genet Cytogenet; 2008 Apr; 182(2):136-9. PubMed ID: 18406877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome.
    Kovacs ME; Papp J; Szentirmay Z; Otto S; Olah E
    Hum Mutat; 2009 Feb; 30(2):197-203. PubMed ID: 19177550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenicity of A600V variant in exon 12 of the MSH2 gene detected in a Japanese kindred with Lynch syndrome.
    Miyakura Y; Sugano K; Nomizu T; Lefor A; Yasuda Y
    Jpn J Clin Oncol; 2012 Jan; 42(1):78-82. PubMed ID: 22086974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.
    Wielders EA; Hettinger J; Dekker R; Kets CM; Ligtenberg MJ; Mensenkamp AR; van den Ouweland AM; Prins J; Wagner A; Dinjens WN; Dubbink HJ; van Hest LP; Menko F; Hogervorst F; Verhoef S; te Riele H
    J Med Genet; 2014 Apr; 51(4):245-53. PubMed ID: 24501230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations.
    Buecher B; De Pauw A; Bazire L; Houdayer C; Fievet A; Moncoutier V; Farkhondeh F; Melaabi S; Lyonnet DS; Golmard L
    Fam Cancer; 2018 Apr; 17(2):281-285. PubMed ID: 28819700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MSH2 c.1022T>C, p.Leu341Pro is a founder pathogenic variation and a major cause of Lynch syndrome in the North of France.
    Vermaut C; Leclerc J; Vasseur F; Wacrenier A; Lovecchio T; Boidin D; Rebergue MH; Cattan S; Manouvrier S; Lejeune S; Buisine MP
    Genes Chromosomes Cancer; 2020 Feb; 59(2):111-118. PubMed ID: 31433521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.
    Alqahtani M; Edwards C; Buzzacott N; Carpenter K; Alsaleh K; Alsheikh A; Abozeed W; Mashhour M; Almousa A; Housawi Y; Al Hawwaj S; Iacopetta B
    Fam Cancer; 2018 Apr; 17(2):197-203. PubMed ID: 28643016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
    Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
    Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of new founder Alu-mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype.
    Pérez-Cabornero L; Borrás Flores E; Infante Sanz M; Velasco Sampedro E; Acedo Becares A; Lastra Aras E; Cuevas González J; Pineda Riu M; Ramón y Cajal Asensio T; Capellá Munar G; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1546-55. PubMed ID: 21778331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.